Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation

Inik Chang, Yozo Mitsui, Seul Ki Kim, Ji Su Sun, Hye Sook Jeon, Jung Yun Kang, Nam Ju Kang, Shinichiro Fukuhara, Ankurpreet Gill, Varahram Shahryari, Z. Laura Tabatabai, Kirsten L. Greene, Rajvir Dahiya, Dong Min Shin, Yuichiro Tanaka

Research output: Contribution to journalArticle

13 Citations (Scopus)


Cytochrome P450 1B1 (CYP1B1) is recognized as a universal tumor biomarker and a feasible therapeutic target due to its specific overexpression in cancer tissues. Despite its up-regulation in prostate cancer (PCa), biological significance and clinicopathological features of CYP1B1 are still elusive. Here, we show that overexpression or hyperactivation of CYP1B1 stimulated proliferative, migratory and invasive potential of non-tumorigenic PCa cells. Attenuation of CYP1B1 with its specific small hairpin (sh) RNAs greatly reduced proliferation through apoptotic cell death and impaired migration and invasion in PCa cells. Intratumoral injection of CYP1B1 shRNA attenuated growth of pre-existing tumors. The antitumor effect of CYP1B1 shRNA was also observed in prostate tumor xenograft mouse models. Among the genes altered by CYP1B1 knockdown, reduction of caspase-1 (CASP1) activity attenuated the antitumor effect of CYP1B1 inhibition. Indeed, CYP1B1 regulates CASP1 expression or activity. Finally, CYP1B1 expression was increased in higher grades of PCa and overall survival was significantly reduced in patients with high levels of CYP1B1 protein. CYP1B1 expression was reversely associated with CASP1 expression in clinical tissue samples. Together, our results demonstrate that CYP1B1 regulates PCa tumorigenesis by inhibiting CASP1 activation. Thus, the CYP1B1-CASP1 axis may be useful as a potential biomarker and a therapeutic target for PCa.

Original languageEnglish
Pages (from-to)39087-39100
Number of pages14
Issue number24
Publication statusPublished - 2017 Jan 1


All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Chang, I., Mitsui, Y., Kim, S. K., Sun, J. S., Jeon, H. S., Kang, J. Y., Kang, N. J., Fukuhara, S., Gill, A., Shahryari, V., Laura Tabatabai, Z., Greene, K. L., Dahiya, R., Shin, D. M., & Tanaka, Y. (2017). Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation. Oncotarget, 8(24), 39087-39100.